Great Valley Advisor Group’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Great Valley Advisor Group’s Portfolio MDNA Stock Details MDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-19,500	Closed	-$5.75K	–	763
2023 Q3	$5.75K	Hold	19,500	–	–	﹤0.01%	672
2023 Q2	$9.39K	Hold	19,500	–	–	﹤0.01%	699
2023 Q1	$12.3K	Hold	19,500	–	–	﹤0.01%	689
2022 Q4	$8.93K	Hold	19,500	–	–	﹤0.01%	687
2022 Q3	$16K	Hold	19,500	–	–	﹤0.01%	662
2022 Q2	$23K	Buy	+19,500	New	+$20.8K	﹤0.01%	660

Other funds holding MDNA

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

NDSI

Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Great Valley Advisor Group's MDNA Position: Q4 2023 in Review

Great Valley Advisor Group sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 19,500 shares — an estimated $5.75K sold.

Great Valley Advisor Group first reported a position in MDNA in Q2 2022 and held it in 6 quarters. The position peaked at $23K in Q2 2022. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

Great Valley Advisor Group reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
Great Valley Advisor Group sold 19,500 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $5.75K.
Great Valley Advisor Group first reported a position in Medicenna Therapeutics Corp. Common Shares in Q2 2022 and held it in 6 quarters.
Great Valley Advisor Group's Medicenna Therapeutics Corp. Common Shares position peaked at $23K in Q2 2022.
3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Great Valley Advisor Group's 13F filing for Q4 2023, filed 6 Feb 2024.